ClinicalTrials.gg
Active, not recruitingNCT05287412MUSICUpdated Mar 27, 2026

Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children

An observational study in Multisystem Inflammatory Syndrome in Children (MIS-C), sponsored by Carelon Research. Active, not recruiting at 33 sites in 2 countries. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Carelon Research · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
Up to 21 Years
Sex
All
01

Study summary

Multi-system Inflammatory Syndrome in Children (MIS-C) is a new condition related to COVID-19, the study investigators are still learning about its causes, effects, and long-term impact. "Long-Term Outcomes after the Multisystem Inflammatory Syndrome In Children", the Coronavirus MUSIC Study, is a research study funded by NIH and the National Heart, Lung, and Blood Institute. The study investigators hope to enroll at least 900 young people with MIS-C at children's medical centers in the U.S. and Canada. This research study will help us learn more about MIS-C and its effects on the long-term health of children.

Read the detailed description

This study is an observational cohort study that will use routinely collected clinical and cardiac (EKG, echocardiogram, Cardiac MRI, exercise testing) data to assess the association between MIS-C and cardiac outcomes within the first year after hospital discharge. Research funding will be available for EKGs, echocardiograms and MRIs in protocol windows that are not ordered by primary caregivers. The principal goal is to determine the spectrum and early time course of coronary artery involvement, LV systolic function, and arrhythmias or conduction system abnormalities, and, using these data, to define associated clinical and laboratory factors. The study investigators planned to include all eligible patients, including retrospective cases beginning January 1, 2020, with follow-up (in-person or telehealth) to up within one year and annual medical history forms until up to 5 years have elapsed since illness onset. Because many patients will have been identified by retrospective review, the study team will obtain consent at different times in their illness course. For this reason, it may be hard to reach some patients and their families. Waiver of consent will be obtained after three attempts have been made to locate the patient and family without success, as well as for the rare child who dies before informed consent can be obtained. The study investigators will include a HIPAA-compliant cryptographic algorithm to create a sharable "hashed" identifier from patient information. If blood work for research purposes is added on to usual clinically indicated blood work during follow-up visits, this will be covered by other informed consent forms.

02

Conditions studied

  • Multisystem Inflammatory Syndrome in Children (MIS-C)

Keywords

  • COVID
03

In context

pediatric multisystem inflammatory disease, COVID-19 related

29 studies on the registry are indexed under pediatric multisystem inflammatory disease, COVID-19 related; 8 are open to participants now.

This study's enrollment of 1,200 is above the median of 212 across 22 observational studies indexed under pediatric multisystem inflammatory disease, COVID-19 related.

Browse pediatric multisystem inflammatory disease, COVID-19 related studies →

Lead sponsor

Carelon Research is the lead sponsor of 59 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

children and young adults \<21 years with Multisystem Inflammatory Syndrome in Children associated with COVID-19 (MIS-C) at a participating hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age \<21 years.
  2. Fever ≥38°C for ≥24 hours, or report of subjective fever lasting ≥24 hours.
  3. Laboratory evidence of inflammation, including, but not limited to, one or more of the following: an elevated CRP, ESR, fibrinogen, procalcitonin, d-dimer, ferritin, LDH, or IL-6, elevated neutrophils, reduced lymphocytes and low albumin.
  4. Evidence of clinically severe illness requiring hospitalization, with multisystem (≥2) organ involvement, based on clinical judgment from record review, discharge diagnosis, laboratory or diagnostic tests. Organ system involvement includes but is not limited to cardiac, renal, respiratory, hematologic including coagulopathy, gastrointestinal including liver, dermatologic or neurological.
  5. Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms

Exclusion criteria

Exclusion Criteria:

  • No plausible alternative diagnosis, such as bacterial sepsis, murine typhus, staphylococcal or streptococcal shock syndromes
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. worst-ever LV ejection fraction

    worst left ventricular (LV) ejection fraction from core lab echo read during MUSIC study

    Time frame: hospital admission through 5 years post-hospitalization

  2. worst-ever maximum z score of the proximal LAD or RCA

    worst maximum z-score of the proximal left anterior descending coronary artery (LAD) or right coronary artery (RCA) from core lab echo read; z-scores to be calculated via Boston z-score calculator (primary) and Pediatric Heart Network z-score calculator (secondary); higher z-scores are worse

    Time frame: hospital admission through 5 years post-hospitalization

Secondary outcomes

  1. Occurrence of a proximal LAD or RCA z score of ≥2.5 on any echocardiogram

    proximal left anterior descending coronary artery (LAD) or right coronary artery (RCA) ≥2.5 from any core lab echo read

    Time frame: hospital admission through 5 years post-hospitalization

  2. Occurrence of aneurysms by Japanese Ministry of Health criteria

    Occurrence of aneurysms by Japanese Ministry of Health criteria applied to core lab echo reads

    Time frame: hospital admission through 5 years post-hospitalization

  3. Individual z scores for LMCA, RCA and LAD

    Individual z scores for left main coronary artery (LMCA), right coronary artery (RCA) and proximal left anterior descending coronary artery (LAD) as per core lab echo reads; higher z-scores are worse

    Time frame: hospital admission through 5 years post-hospitalization

  4. LVEDV z score

    left ventricular (LV) size as measured by left ventricular end-diastolic volume (LVEDV) z score

    Time frame: hospital admission through 5 years post-hospitalization

  5. LVEF

    left ventricular (LV) function as measured by left ventricular ejection fraction (LVEF)

    Time frame: hospital admission through 5 years post-hospitalization

  6. LVSF

    left ventricular (LV) function as measured by left ventricular shortening fraction (LVSF)

    Time frame: hospital admission through 5 years post-hospitalization

  7. The percentage of patients who had LV ejection of <55%, and further categorization of 45-54% (i.e., mildly depressed systolic function), 35-44% (moderately depressed systolic function) and <35% (severely depressed systolic function) on any echocardiogram

    The percentage of patients who had left ventricular (LV) ejection of \<55%, and further categorization of 45-54% (i.e., mildly depressed systolic function), 35-44% (moderately depressed systolic function) and \<35% (severely depressed systolic function) on any echocardiogram read by the core lab

    Time frame: hospital admission through 5 years post-hospitalization

  8. LV strain (global longitudinal strain from apical view and global circumferential strain from parasternal short-axis view)

    left ventricular (LV) strain (global longitudinal strain from apical view and global circumferential strain from parasternal short-axis view) on core lab echo read

    Time frame: hospital admission through 5 years post-hospitalization

  9. Qualitative assessment of RV systolic function

    Qualitative assessment of right ventricular (RV) systolic function on core lab echo read

    Time frame: hospital admission through 5 years post-hospitalization

  10. Qualitative assessment of RV global longitudinal strain

    Qualitative assessment, if possible, of right ventricular (RV) global longitudinal strain on core lab echo read

    Time frame: hospital admission through 5 years post-hospitalization

  11. Presence and degree of mitral and aortic regurgitation

    Presence and degree of mitral and aortic regurgitation on echo core lab read

    Time frame: hospital admission through 5 years post-hospitalization

  12. LV diastolic function, i.e., tissue Doppler imaging and mitral valve (MV) inflow

    left ventricular (LV) diastolic function, i.e., tissue Doppler imaging and mitral valve (MV) inflow on echo core lab read

    Time frame: hospital admission through 5 years post-hospitalization

  13. Presence and size of pericardial effusion

    Presence and size of pericardial effusion on echo core lab read

    Time frame: hospital admission through 5 years post-hospitalization

  14. The occurrence of arrhythmias and conduction system disturbances by in-hospital monitoring, electrocardiograms, and exercise testing at 3 months in those with a history of ≥moderate systolic dysfunction when age and maturity permit

    The occurrence of arrhythmias and conduction system disturbances by in-hospital monitoring, electrocardiograms, and exercise testing at 3 months in those with a history of ≥moderate systolic dysfunction when age and maturity permit

    Time frame: 3 months post-discharge

  15. MRI LVEF

    LVEF on MRI core lab read

    Time frame: hospital admission through 5 years post-hospitalization

  16. MRI RVEF

    RVEF on MRI core lab read

    Time frame: hospital admission through 5 years post-hospitalization

  17. valvar regurgitation

    valvar regurgitation on MRI core lab read

    Time frame: hospital admission through 5 years post-hospitalization

  18. myocardial late gadolinium enhancement (LGE)

    percent with and distribution of myocardial late gadolinium enhancement (LGE) on MRI core lab read

    Time frame: hospital admission through 5 years post-hospitalization

  19. abnormal T2-weighted imaging

    percent abnormal T2-weighted imaging on MRI core lab read

    Time frame: hospital admission through 5 years post-hospitalization

  20. elevated T2

    percent with elevated T2 on MRI core lab read

    Time frame: hospital admission through 5 years post-hospitalization

  21. elevated native T1

    percent with elevated native T1 on MRI core lab read

    Time frame: hospital admission through 5 years post-hospitalization

  22. elevated extracellular volume fraction

    percent with elevated extracellular volume fraction on MRI core lab read

    Time frame: hospital admission through 5 years post-hospitalization

  23. coronary artery dilation

    percent with coronary artery dilation on MRI core lab read

    Time frame: hospital admission through 5 years post-hospitalization

  24. CMR abnormal, equivocal, or negative

    final interpretation of CMR as abnormal, equivocal, or negative (i.e., no abnormal or equivocal findings) on MRI core lab read

    Time frame: hospital admission through 5 years post-hospitalization

  25. Other organ abnormalities by medical history: Immunologic, rheumatologic, renal, pulmonary, hematologic, gastrointestinal, dermatologic or neurologic

    percent with other organ abnormalities by medical history: Immunologic, rheumatologic, renal, pulmonary, hematologic, gastrointestinal, dermatologic or neurologic

    Time frame: hospital admission through 5 years post-hospitalization

  26. CRP

    C-Reactive Protein (CRP) as a laboratory marker of inflammation

    Time frame: hospital admission through 5 years post-hospitalization

  27. Admission to ICU

    percent with admission to ICU

    Time frame: hospital admission through 5 years post-hospitalization

  28. Maximal vasoactive inotrope score

    Maximal vasoactive inotrope score

    Time frame: from MIS-C hospital admission to MIS-C hospital discharge

  29. Hospital length of stay

    Hospital length of stay

    Time frame: from MIS-C hospital admission to MIS-C hospital discharge

  30. Symptom duration

    Symptom duration

    Time frame: hospital admission through 5 years post-hospitalization

  31. Major medical events

    percent with major medical events (e.g., stroke, need for extracorporeal therapies such as renal replacement therapy, plasma exchange, ECMO, VAD)

    Time frame: hospital admission through 5 years post-hospitalization

  32. Mortality

    Percent mortality

    Time frame: hospital admission through 5 years post-hospitalization

  33. Global Health - FSS

    Global Health as measured by Functional Status Score \[FSS\]: range 6-30, lower is better

    Time frame: hospital admission through 5 years post-hospitalization

  34. Global Health - PROMIS

    Global Health as measured by Parent-Reported Outcomes Measurement Information Systems \[PROMIS\] Instrument: range 7-35, higher is better

    Time frame: hospital admission through 5 years post-hospitalization

07

Study locations

33 sites
08

References and documents

Publications

  • Lang SM, Truong DT, Powell AJ, Kazlova V, Newburger JW, Awerbach JD, Binka E, Bradford TT, Cartoski M, Cheng A, DiLorenzo MP, Dionne A, Dorfman AL, Elias MD, Garuba O, Gerardin JF, Hasbani K, Jone PN, Lam CZ, Misra N, Morgan LM, Nutting A, Patel JK, Robinson JD, Schuchardt EL, Sexson Tejtel K, Singh GK, Slesnick TC, Trachtenberg F, Taylor MD; MUSIC Study Investigators. CMR Findings in the Long-Term Outcomes After Multisystem Inflammatory Syndrome in Children (MUSIC) Study. Circ Cardiovasc Imaging. 2025 Sep;18(9):e017420. doi: 10.1161/CIRCIMAGING.124.017420. Epub 2025 Apr 4. PubMed 40181776 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Jul 2026, 70 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2022
First posted
Mar 18, 2022
StartActual
Sep 30, 2020
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05287412
Lead sponsor
Carelon Research
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
Sep 30, 2020
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Mar 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion